Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.49 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1057299 | 0.89 | SPPL2A (0.52) | TAS2R14 | |
| SCHEMBL1058578 | 0.87 | SPPL2A (0.48) | TAS2R14 | |
| SCHEMBL2578425 | 0.87 | PTGES (0.53) | PTGESTAS2R14TAS2R8 | |
| SCHEMBL5928397 | 0.87 | PTGES (0.53) | PTGESTAS2R14TAS2R8 | |
| SCHEMBL1053311 | 0.86 | SPPL2A (0.48) | TAS2R14 | |
| SCHEMBL1059096 | 0.86 | SPPL2A (0.48) | TAS2R14 | |
| SCHEMBL611342 | 0.86 | SPPL2A (0.47) | TAS2R14 | |
| SCHEMBL28778215 | 0.86 | SPPL2A (0.47) | TAS2R14 | |
| SCHEMBL1055848 | 0.84 | SPPL2A (0.46) | TAS2R14 | |
| SCHEMBL12621038 | 0.84 | SPPL2A (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193227-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110003827-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2011-01-06 | — | — | US | disclosed |
| US-20050131042-A1 | HIV protease inhibiting compounds | ABBOTT LABORATORIES | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003827-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | PTGES 2229/4885TAS2R14 4673/4885TAS2R8 4842/4885 |
| US-20050131042-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | PTGES 2229/4885TAS2R14 4673/4885TAS2R8 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.